Lewy Bodies in the Amygdala
|
|
- Griffin Gordon
- 5 years ago
- Views:
Transcription
1 ORIGINAL CONTRIBUTION Lewy Bodies in the Amygdala Increase of -Synuclein Aggregates in Neurodegenerative Diseases With Tau-Based Inclusions Anca Popescu, MD; Carol F. Lippa, MD; Virginia M.-Y. Lee, PhD; John Q. Trojanowski, MD, PhD Background: Increased attention has been given to -synuclein aggregation in nonsynucleinopathies because -synuclein containing Lewy bodies (LBs) influence symptoms. However, the spectrum of disorders in which secondary inclusions are likely to occur has not been defined. Amygdala neurons commonly develop large numbers of secondary LBs, making it a practical region for studying this phenomenon. Objective: To characterize the spectrum of diseases associated with LB formation in the amygdala of neurodegenerative disease and control cases. Design: An autopsy series of 101 neurodegenerative disease and 34 aged control cases. Using immunohistochemistry studies, we examined the amygdala for -synuclein aggregates. Results: Lewy bodies were often abundant in classic Pick disease, argyrophilic grain disease, Alzheimer disease, and dementia with LBs but not in cases with amygdala degeneration lacking tau-based inclusions, control cases, preclinical disease carriers, or degenerative diseases lacking pathologic involvement of the amygdala. The exposed -synuclein epitopes were similar in all cases containing LBs. Conclusions: Abnormal -synuclein aggregation in the amygdala is disease selective, but not restricted to disorders of -synuclein and -amyloid. Our data are compatible with the notion that tau aggregates predispose neurons to develop secondary LBs. Arch Neurol. 2004;61: Author Affiliations: Department of Neurology, Drexel University College of Medicine (Drs Popescu and Lippa), and Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine (Drs Lee and Trojanowski), Philadelphia. AGGREGATION OF -SYnuclein has a primary pathogenic role in sporadic and familial autosomal dominant Parkinson disease, multiple system atrophy (MSA), and dementia with Lewy bodies (DLB). 1-6 In the past few years, increased -synuclein aggregation in the form of Lewy bodies (LBs) has been reported in neurodegenerative diseases that are not synucleinopathies. 7-9 In this context, LBs may be considered a secondary phenomenon that reflects the fibrillation of -synuclein induced directly by the formation of fibrillary tau lesions or indirectly by cell stress resulting from the formation of these tau inclusions. Regulatory factors involved in -synuclein expression and the biological changes leading to primary or secondary -synuclein aggregation in neurodegenerative diseases are not well understood. Secondary LBs are numerous in the amygdala and adjacent entorhinal cortex in cases of Alzheimer disease (AD), including sporadic and familial AD, and Down syndrome (DS). They occur in at least half of these subjects. 7-9 It is unknown whether this curious finding is restricted to AD, or whether it is a more universal phenomenon. In the present study, we compared -synuclein immunoreactivity in the amygdala in a variety of diseases, including disorders of tau, -synuclein, and -amyloid, and in control cases to determine how widespread this phenomenon is. We also examined epitope exposure in LBs to screen for obvious differences in LB conformation in different diseases. METHODS We examined 135 amygdala specimens from pathologically confirmed cases meeting consensus pathological criteria for DLB 10 (n=9; LBs were common in regions outside the amygdala), sporadic AD 11 (n=20; lacking LBs outside the amygdala), DS (n=9; with or without evidence of cognitive and/or functional decline), early-onset familial AD with presenilin-1 mutations (n=6), preclinical AD with a presenilin-1 mutation (n=1), classic Pick disease 12 (PiD) (n=6; frontotemporal dementia with numerous Pick bodies; not meeting con- 1915
2 Table. Summary Table Showing the Incidence of LBs and the Average Severity of LB Pathology Across Diseases Diagnosis No. of Cases current criteria for AD 11 ), dementia lacking distinctive histopathological features 12 (DLDH) (n=40), amyotrophic lateral sclerosis (ALS) (n=4), MSA (n=3), argyrophilic grain disease (AGD) (n=2), progressive supranuclear palsy (PSP) (n=1), and cognitively normal elderly control cases lacking significant neurological diagnoses (n=34) (Table). Control cases had documentation of a normal mental status during life, lacked other neurological diagnoses before death, and did not meet pathological criteria for AD or other disorders. All cases, except DLB cases, lacked -synuclein pathology in other regions, including brainstem structures. Formalin-fixed, paraffin-embedded tissue was sectioned at 6 µm at the level of the midamygdala and stained with a wellcharacterized monoclonal antibody (LB509) 1 to purified fulllength recombinant -synuclein. The antibody LB509 was generated with partially purified LBs as the antigen and was subsequently proved to recognize -synuclein. Some tissues reactive for LB509 were then immunostained using a panel of monoclonal antibodies (SNL-4, 204, LB509, 211, and 202) described previously 13 that are directed at epitopes throughout the -synuclein protein. Formic acid pretreatment was used with all antibodies. 13 The -synuclein epitopes were detected using avidinbiotin complex kits (Vector Laboratories, Burlingame, Calif) and 3,3 -diaminobenzidine. Positive control tissue consisted of affected regions of a DLB case. Consecutive sections where the supernatant from unfused SP2/0-Ag14 mouse myeloma cells replaced the primary antibodies were used as negative control tissue. A previously defined semiquantitative scale 8,9 for rating of LBs was used, where 0 indicates no LBs in the amygdala; 1, 1 to 5; 2, 6 to 20; and 3, more than 20 per amygdala. Since LBs were more numerous than envisioned when the scale was developed, we added grade 4 to indicate an average of more than 20 LBs per high-power field. We rated -synuclein positive threads (Lewy neurites) on a 0- to 3-point scale. All grading was performed by 2 observers (A.P. and C.F.L.), who were blinded to diagnosis. RESULTS No. (%) of Cases With LBs Mean LB Score DLB 9 8 (89) 2.9 PS-1 AD 7 4 (57) 1.7 PiD 6 3 (50) 1.3 DS 9 4 (44) 1.3 AGD 2 1 (50) 1.5 SAD 20 7 (35) 0.7 DLDH 40 2 (5) 0.1 Aged normal controls* 34 1 (3) 0.1 ALS MSA PSP Abbreviations: AD, Alzheimer disease; AGD, argyrophilic grain disease; ALS, amyotrophic lateral sclerosis; DLB, dementia with LBs; DLDH, dementia lacking distinctive histopathological features; DS, Down syndrome; LB, Lewy body; MSA, multiple system atrophy; PiD, Pick disease; PS-1 AD, AD related to presenilin-1 mutations; PSP, progressive supranuclear palsy; SAD, sporadic AD. *Indicates elderly subjects with no significant neurological disease. Using the LB509 antibody, we confirmed our previous finding that LBs are common in the amygdala of patients with DLB and AD. Moreover, we made the novel observation that LBs were also often present in the amygdala of PiD cases. Three of the 6 PiD cases studied showed numerous LBs in the amygdala (Figure). Rare diffuse amyloid plaques were present in the amygdala of 1 PiD case; the other 2 cases lacked plaques. Lewy bodies were also numerous in 1 case of AGD, another tau disorder involving the amygdala. Lewy bodies were rare in neurodegenerative diseases where the amygdala is not heavily involved by the disease process (ALS and PSP). In MSA, occasional glial cytoplasmic inclusions in the surrounding white matter were immunoreactive for -synuclein, but intraneuronal aggregates were not seen. Lewy bodies and Lewy threads were present in only 2 of 40 cases of DLDH, although severe neuronal loss was seen in most amygdalae. Amygdala LBs were also absent in cases with amyloid plaques but no neurofibrillary tangles (the younger patients with DS and our patient with a preclinical presenilin-1 mutation). In cases where LBs are present, the LB density is typically higher than that described in other brain regions. 11 Our semiquantitative grading (reported as mean±sd grade) indicated that the highest number of LBs occurred in DLB (2.9±1.1; 8 of 9 cases), followed by familial AD (1.7±1.9; 4 of 7 cases), AGD ( ; 1 of 2 cases), DS (1.3±1.6; 4 of 9 cases), PiD (1.3±1.6; 3 of 6 cases), sporadic AD (0.7±1.1; 7 of 20 cases), and DLDH (0.08±0.4; 2 of 40 cases). Lewy bodies were also almost never observed in the amygdalae of aged, cognitively normal control cases (0.1±0.1; 1 of 34 cases). When present in AD, DLB, AGD, and PiD, LBs were almost always graded 3 or 4. When grade 3 changes were present, the superficial regions (central and medial nuclei) tended to be more heavily involved. However, the atrophy and gliosis were too severe to allow us to distinguish exact borders between subregions, so we did not attempt to compare the subregions. In cases where grade 4 changes were present, LBs occurred throughout the amygdala. Lewy body density was low in DLDH, and the 2 cases with LBs were graded 1 and 2. We usually found -synuclein positive threads in cases with an LB burden of 2 or greater. They were most common in DLB (mean±sd grade, 1.3±0.9), but were also present in familial AD (1±1.3), DS (0.8±1.3), PiD (0.4±0.9), AGD (0.5±0.7), and sporadic AD (0.18±0.38). Lewy threads were not present in cases lacking LBs. Because LBs in amyloidopathies are often restricted to the amygdala, we characterized the distribution of LBs in the PiD cases by screening other brain regions containing Pick bodies, including the frontal cortex (middle frontal and cingulate gyri), temporal lobe (entorhinal cortex and hippocampus), and brainstem (locus coeruleus, midbrain, and medulla). In PiD cases where amygdala LBs were abundant, we observed occasional LBs in the periamygdaloid entorhinal cortex. One PiD case lacking LBs in the amygdala had an isolated LB in the locus coeruleus. Lewy bodies were absent in other areas. Because focal LBs are not commonly described in high densities in tauopathies, we further examined the PiD cases using double-label immunohistochemistry studies to determine how frequently LBs coexisted with Pick bodies. Double-label studies with -synuclein and tau 1916
3 A B C D E F G H I J K L M Figure. Photomicrographs of -synuclein expression in neurodegenerative disease cases. Lewy bodies (LBs) positive for -synuclein are absent in the amygdalae of cognitively normal cases using the LB509 antibody (A). In contrast, LBs (identified with the LB509 antibody) are numerous in the amygdala in Alzheimer disease (B), dementia with LB (C), and classic Pick disease (D). Lewy bodies are absent in amyotrophic lateral sclerosis (E) and the negative control slide (H, primary antibody omitted). Double-label immunohistochemistry studies demonstrate that in Pick disease, the LBs ( -synuclein, fast red/red) and Pick bodies (tau-2, diaminobenzidine/brown) may commix (F) or LBs may be more discrete (G). The LB grading scale is as follows: 0 indicates no LBs in the amygdala (I); 1, 1-5 (J); 2, 6-20 (K); 3, more than 20 per amygdala (L); and 4, more than 20 per high-power field (M). Cases with an LB grade of 4 also contain numerous Lewy threads. Scale bar indicates 20 µm in parts A through E and I through M, 10 µm in parts F and G, and 60 µm in part H. demonstrated that LBs in PiD usually colocalized with tau-positive Pick bodies. Here, both proteins could be commixed, although sometimes the inclusions remained discrete, with a Pick body adjacent to the LB. When we obtained counts in a band of adjacent fields across the medial-to-lateral amygdala in PiD cases, taupositive immunoreactivity was present in 82% of neurons containing -synuclein aggregates. Only 18% of PiD neurons with LBs lacked clear-cut tau aggregates in the same section. This is similar to our AD and DS cases where LBs typically colocalize with tau-positive neurofibrillary tangles. 8,9 To address the question of whether secondary -synuclein exposure was similar in all diseases, we examined our cases containing LBs with the additional epitope-specific -synuclein antibodies described in the Methods section. When we compared the epitope-mapping properties of LBs in PiD with those in familial and sporadic AD, DS, and DLB, we found epitope mapping to be identical with strong exposure of all epitopes. In contrast, our MSA cases showed nonuniform epitope mapping in glial aggregates, with amino-terminal epitopes showing less consistent immunoreactivity. This finding is consistent with epitope mapping in other MSA studies. 13 COMMENT We report for the first time, to our knowledge, the presence of intraneuronal -synuclein aggregates in the PiD amygdala, a region heavily affected with Pick bodies. Despite the small PiD sample size, it was clear that LBs were abundant when present, sometimes reaching densities of greater than 20 per high-power field. They usually colocalized with Pick bodies. In our AD cases, LBs colocalized with tau-positive neurofibrillary tangles. One of our AGD cases also had amygdala LBs, supporting the notion that tau is important in the process of LB formation. Because AGD is a 4-repeat (4R) tau disorder, PiD is a 3R tau disorder, and AD has equal tau ratios, our data suggest that amygdala LBs occur regardless of the 3R:4R tau ratio. Progressive supranuclear palsy, a tauopathy lacking amygdala LBs, also lacked tau aggregates in the amygdala. Secondary LBs developed less commonly in con- 1917
4 trol cases, asymptomatic carriers (those with early DS and the preclinical case with the presenilin-1 mutation), and degenerative disease cases lacking tau aggregates (DLDH). Preexisting amygdala pathology appears to be an important factor in LB formation. The frequent colocalization of tau and -synuclein in the same neuron in diseases with tau aggregates and the rare occurrence of LBs in diseases without tau pathology (normal controls and DLDH) speak for an association between tau and -synuclein aggregation that could directly or indirectly be mediated by tau inclusions that promote the fibrillation of -synuclein to form LBs in regions with abundant fibrillary tau lesions. Immunoreactivity of -synuclein has previously been reported in tauopathies. Although nigral LB counts did not differ between control subjects and those with PSP, Tsuboi and colleagues 14 found LBs and Lewy neurites in 18% of PSP cases, with amygdala LBs being one of the most involved regions. Using epitope specific antibodies, Takeda et al 15 found that a C-terminus fragment -synuclein antibody stained tau-positive aggregates in AD, PSP, corticobasal degeneration, and PiD. These interesting findings support the notion that -synuclein fragments commonly co-occur with pathologic tau inclusions. Evidence of an interaction between tau and -synuclein at a biochemical level has also been found. Microtubule-associated, soluble axonal tau protein binds to the C-terminus of -synuclein, which in turn modulates tau phosphorylation. 16 It could be argued that -synuclein aggregates are not true LBs if they do not have a fibrillary nature. A previous study from our group demonstrated the fibrillary structure of amygdala LBs by means of electron microscopy. 8 Thioflavine stains have also demonstrated the fibrillary nature of these lesions. The common coexistence of LBs and tau aggregates (neurofibrillary tangles, Pick bodies, or 4R grains) could be related to failure of tau function (including microtubule assembly and/or axonal transport) or could be a direct effect of the tau aggregate. Tau hyperphosphorylation may lead to structural changes in -synuclein that accelerate its aggregation. Another possibility is that impaired axonal transport leads to backup and concentration of -synuclein in the cytoplasm, which predisposes to fibrillogenesis and aggregation. However, since AGD grains most commonly occur in dendrites, we do not think the process is triggered exclusively within the axon. Alternatively, the LBs may form as more of a general compensatory response to cell stress or other perturbations resulting from the accumulation of filamentous tau aggregates. 17 The reason why the amygdala is susceptible to LB formation is unknown. Tsuchiya et al 18 studied 8 autopsied classic PiD cases and found that the amygdala showed the most severe lesions of all basal ganglia regions. In our 3 cases with PiD and LBs in the amygdala, none had LBs in the basal ganglia or brainstem (except for 1 case with LBs in the locus coeruleus). Yamazaki et al 19 reported 5 cases of Guam dementia complex with -synuclein positive inclusions in the amygdala reminiscent of cortical LBs. These coexisted with tau-positive pretangles and/or neurofibrillary tangles. Overall, the amygdala can be viewed as an area susceptible to primary and secondary -synuclein inclusions, although the reasons for this remain elusive. Indeed, Marui et al 20 recently reported that Lewy pathology in the cerebrum begins in the amygdala in LB disease. This differs from the staging system for PD, where pathology starts in the medulla. 21 We examined other brain regions in our cases, including the medulla, and found little subcortical -synuclein pathology. This is in keeping with the findings of Jellinger, 22 who also noted that -synuclein aggregates in AD do not follow the regional pattern of distribution described by Braak et al 21 for PD. One interesting question is whether the formation of LBs in the amygdala influences the clinical course. Lewy bodies influence symptoms in AD cases, even when they are present in much lower densities. 23 Results of retrospective medical chart reviews in cases where history was available showed only occasional cases with classic features of DLB (spontaneous parkinsonism or visual hallucinations). However, PD cases with amygdala LBs have more visual hallucinations than comparable PD cases lacking amygdala LBs. 24 Although the preexisting tau pathology and neuronal loss makes it likely that the clinical presentations would have features of the primary disorder, prospective studies are needed to more fully determine to what extent, if any, amygdala LBs have an impact on symptoms. It is possible that these subjects would experience differential involvement of autonomic, olfactory, visceral, endocrine, affective, and mnemonic activities (which are subserved by intra-amygdala circuits). Disease duration did not correlate strongly with the presence of LBs. The mean duration of illness in PiD cases with LBs in amygdala was 12.7 years (range, 3-17 years), whereas in non LB-containing PiD cases, it was 17.8 years (range, years). The Braak AD stage was VI 25 in almost all of our postmortem symptomatic AD cases, regardless of whether amygdala LBs were present. Our symptomatic cases all had end-stage symptoms at death, requiring assistance for all activities of daily living. This made it impossible to determine whether LB formation is related to symptom severity. However, LBs did not occur in young patients with DS or in the case with preclinical, presenilin-related AD, suggesting that amygdala LBs are not an early finding. The reason why central nervous system proteins coprecipitate remains fertile ground for future research. A growing body of evidence suggests that one pathologic protein promotes fibrillation of other abnormal proteins. 26 Herein, we focused on cases with tau as a primary aggregate. This study does not address mechanisms involved in secondary (tau) inclusion formation in cases where -synuclein is the primary aggregate, such as the Contursi kindred. 27 The present study also does not completely address whether -amyloid deposition influences amygdala LB formation. However, -amyloid deposition is not crucial for secondary LB formation in the amygdala in PiD, because our affected PiD cases had little -amyloid deposition. Future studies are also needed to explain why the 2 types of pathology overlap only in certain brain regions. It is feasible that all 3 pathologic proteins (tau, -synuclein, and -amyloid) can promote secondary inclusion formation under different cir- 1918
5 cumstances. Future studies are needed to better understand mechanisms by which abnormal processing and/or deposition of one central nervous system protein is related to deposition of other central nervous system proteins. Accepted for Publication: June 18, Correspondence: Carol F. Lippa, MD, Department of Neurology, Drexel University College of Medicine, 3300 Henry Ave, Philadelphia, PA Author Contributions: Study concept and design: Popescu, Lippa, Lee, and Trojanowski. Acquisition of data: Popescu and Lippa. Analysis and interpretation of data: Popescu, Lippa, Lee, and Trojanowski. Drafting of the manuscript: Popescu and Lippa. Critical revision of the manuscript for important intellectual content: Popescu, Lippa, Lee, and Trojanowski. Obtained funding: Lippa. Administrative, technical, and material support: Lippa. Study supervision: Popescu, Lippa, Lee, and Trojanowski. REFERENCES 1. Baba M, Nakajo S, Tu PH, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson s disease and dementia with Lewy bodies. Am J Pathol. 1998;152: Dickson DW, Ruan D, Crystal H, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology. 1991;41: Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998; 57: Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alphasynuclein in Parkinson s disease [letter]. Nat Genet. 1998;18: Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson s disease. Science. 1997;276: Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol. 1998;44: Hamilton RL. Lewy bodies in Alzheimer disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000; 10: Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alphasynuclein in brains of many familial Alzheimer s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;153: Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down s syndrome brains with Alzheimer s disease. Ann Neurol. 1999;45: McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47: National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer s Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer s disease. Neurobiol Aging. 1997;18(suppl 4):S1-S Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. J Neurol Neurosurg Psychiatry. 1994;57: Duda JE, Giasson BI, Gur TL, et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol. 2000;59: Tsuboi Y, Ahlskog JE, Apaydin H, Parisi JE, Dickson DW. Lewy bodies are not increased in progressive supranuclear palsy compared with normal controls. Neurology. 2001;57: Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E. C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol (Berl). 2000;99: Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R. Alphasynuclein binds to tau and stimulates the protein kinase A catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem. 1999;274: Armstrong RA, Cairns NJ, Lantos PL. Are pathological lesions in neurodegenerative disorders the cause or the effect of the degeneration? Neuropathology. 2002;22: Tsuchiya K, Arima K, Fukui T, et al. Distribution of basal ganglia lesions in Pick s disease with Pick bodies. Neuropathology. 1999;19: Yamazaki M, Arai Y, Baba M, et al. Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol. 2000;59: Marui W, Iseki E, Nakai T, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci. 2002;195: Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson s disease (preclinical and clinical stages). J Neurol. 2002;249(suppl 3):III/1-III/ Jellinger KA. Alpha-synuclein pathology in Parkinson s and Alzheimer s disease brain: incidence and topographic distribution a pilot study. Acta Neuropathol (Berl). 2003;106: Hansen LA. The Lewy body variant of Alzheimer disease. J Neural Transm Suppl. 1997;51: Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson s disease. Brain. 2002;125: Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer s disease. Neurobiol Aging. 1997;18:S85-S Giasson BI, Forman MS, Higuchi M, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science. 2003;300: Duda JE, Giasson BI, Mabon ME, et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol (Berl). 2002;104:
Neuropathology of Neurodegenerative Disorders Prof. Jillian Kril
Neurodegenerative disorders to be discussed Alzheimer s disease Lewy body diseases Frontotemporal dementia and other tauopathies Huntington s disease Motor Neuron Disease 2 Neuropathology of neurodegeneration
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationNACC Neuropathology (NP) Diagnosis Coding Guidebook
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationORIGINAL CONTRIBUTION. Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies,
ORIGINAL CONTRIBUTION Apolipoprotein E 4 Is a Determinant for Alzheimer-Type Pathologic Features in Tauopathies, Synucleinopathies, and Frontotemporal Degeneration Keith A. Josephs, MST, MD; Yoshio Tsuboi,
More informationSimulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases
Acta Neuropathol (2011) 122:737 745 DOI 10.1007/s00401-011-0880-5 ORIGINAL PAPER Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases Sriram Venneti John L. Robinson Subhojit
More informationThe Spectrum of Age-Associated Astroglial Tauopathies. Dennis W. Dickson MD Department of Neuroscience Mayo Clinic, Jacksonville, FL
The Spectrum of Age-Associated Astroglial Tauopathies Dennis W. Dickson MD Mayo Clinic, Jacksonville, FL Thorn-shaped astrocytes TSA were first reported by Ikeda (1995), as tau-positive astrocytes in various
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationFDG-PET e parkinsonismi
Parkinsonismi FDG-PET e parkinsonismi Valentina Berti Dipartimento di Scienze Biomediche, Sperimentali e Cliniche Sez. Medicina Nucleare Università degli Studi di Firenze History 140 PubMed: FDG AND parkinsonism
More informationPathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)
Pathogenesis of Degenerative Diseases and Dementias D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria) Dementias Defined: as the development of memory impairment and other cognitive deficits
More informationThe Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina
The Carroll A. Campbell, Jr. Neuropathology Laboratory: A Tool for Dementia Discovery in South Carolina Pathology in the Cerebral Cortex H&E stain of mature neuritic plaque Modified Bielschowsky stain
More informationFinal Scientific Progress Report
CUREPSP Final Scientific Progress Report Tau in Peripheral Tissues of PSP and CBD. Brittany Dugger, PhD; University of California San Francisco Specific Aim: Using immunohistochemical methods on autopsy
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationChronic Traumatic Encephalopathy Provider and Parent Essentials
Chronic Traumatic Encephalopathy Provider and Parent Essentials Concussion Global Cast July 30, 2014 John Lockhart, MD Seattle Children s Hospital Chronic Traumatic Encephaly (CTE) Working Definition Chronic
More informationAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative
ORIGINAL RESEARCH E. Matsusue S. Sugihara S. Fujii T. Kinoshita T. Nakano E. Ohama T. Ogawa Cerebral Cortical and White Matter Lesions in Amyotrophic Lateral Sclerosis with Dementia: Correlation with MR
More informationAutopsy Committee Sample Autopsy Case. Alzheimer Disease. Authors Ashley Thorburn, MD. Joseph E. Parisi, MD Autopsy Committee
Autopsy Committee Sample Autopsy Case Alzheimer Disease Authors Ashley Thorburn, MD Joseph E. Parisi, MD Autopsy Committee Clinical Summary: A 75-year-old man presented to his primary care physician with
More informationORIGINAL CONTRIBUTION. Deposition of -Amyloid Subtypes 40 and 42 Differentiates Dementia With Lewy Bodies From Alzheimer Disease
ORIGINAL CONTRIBUTION Deposition of -Amyloid Subtypes 40 and 42 Differentiates Dementia With Lewy Bodies From Alzheimer Disease Carol F. Lippa, MD; Kazuharu Ozawa, PhD; David M. A. Mann, PhD; Kazuhiro
More informationAltered proteins in the aging brain
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1182 Altered proteins in the aging brain ADILA ELOBEID ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2016 ISSN 1651-6206 ISBN
More informationLewy Body-Related -Synucleinopathy in Aging
Journal of Neuropathology and Experimental Neurology Vol. 6, No. 7 Copyright 4 by the American Association of Neuropathologists July, 4 pp. 74 749 Lewy Body-Related -Synucleinopathy in Aging YUKO SAITO,
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationOBSERVATION. Absence of -Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia
OBSERVATION Absence of -Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia Stéphanie Bombois, MD; Claude-Alain Maurage, MD, PhD; Marie Gompel, PhD; Vincent Deramecourt, MD;
More informationType 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky
Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationSPATIAL PATTERNS OF THE TAU PATHOLOGY IN PROGRESSIVE SUPRANUCLEAR PALSY
SPATIAL PATTERNS OF THE TAU PATHOLOGY IN PROGRESSIVE SUPRANUCLEAR PALSY Richard A. Armstrong 1* and Nigel J. Cairns 2 1 Vision Sciences, Aston University, Birmingham B4 7ET, UK; 2 Departments of Neurology,
More informationThe relationship between development of neuronal and astrocytic tau pathologies. in subcortical nuclei and progression of argyrophilic grain disease
Ikeda et al. The relationship between development of neuronal and astrocytic tau pathologies in subcortical nuclei and progression of argyrophilic grain disease Chikako Ikeda ), Osamu Yokota,,), Shigeto
More informationNACC Vascular Consortium. NACC Vascular Consortium. NACC Vascular Consortium
NACC Vascular Consortium NACC Vascular Consortium Participating centers: Oregon Health and Science University ADC Rush University ADC Mount Sinai School of Medicine ADC Boston University ADC In consultation
More informationOriginal Article Limbic Lobe Microvacuolation is Minimal in Alzheimer s Disease in the Absence of Concurrent Lewy Body Disease
www.ijcep.com/ijcep709002 Original Article Limbic Lobe Microvacuolation is Minimal in Alzheimer s Disease in the Absence of Concurrent Lewy Body Disease Yasuhiro Fujino and Dennis W. Dickson Neuropathology
More informationNew Approach to Parkinson s Disease: Synuclein Immunotherapy
RB2014 Conference August 22, 2014 New Approach to Parkinson s Disease: Synuclein Immunotherapy Dale Schenk, PhD President and CEO Prothena Corporation plc Primary Motor and Non-Motor Symptoms of Parkinson
More informationLewy body disease (LBD) is the second most common
REGULAR ARTICLES Lewy Body Disease: Can We Diagnose It? Michelle Papka, Ph.D. Ana Rubio, M.D., Ph.D. Randolph B. Schiffer, M.D. Christopher Cox, Ph.D. The authors assessed the accuracy of published clinical
More informationFrontotemporal dementia and dementia with Lewy bodies in a case-control study of Alzheimer s disease
International Psychogeriatrics: page 1 of 8 C 2009 International Psychogeriatric Association doi:10.1017/s1041610209009454 Frontotemporal dementia and dementia with Lewy bodies in a case-control study
More informationHallucinations and signs of parkinsonism help distinguish patients with dementia and cortical
161Journal of Neurology, Neurosurgery, and Psychiatry 1997;62:16-21 Alzheimer's Treatment and Research Center, Department of Neurology, Ramsey Clinic/Health- Partners, University of Minnesota, St Paul,
More informationEvaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases
J Neuropathol Exp Neurol Vol. 76, No. 4, April 2017, pp. 270 288 doi: 10.1093/jnen/nlx007 ORIGINAL ARTICLE Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationStaging of Sporadic Parkinson Disease-Related a-synuclein Pathology: Inter- and Intra-Rater Reliability
J Neuropathol Exp Neurol Copyright Ó 2005 by the American Association of Neuropathologists, Inc. Vol. 64, No. 7 July 2005 pp. 623 628 ORIGINAL ARTICLE Staging of Sporadic Parkinson Disease-Related a-synuclein
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationInvited review: Neuropathology of tauopathies: principles and practice
Neuropathology and Applied Neurobiology (2015), 41, 3 23 doi: 10.1111/nan.12208 Invited review: Neuropathology of tauopathies: principles and practice G. G. Kovacs Institute of Neurology, Medical University
More informationDementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology
Dementia Amber Eker, MD Assistant Professor Near East University Department of Neurology Dementia An acquired syndrome consisting of a decline in memory and other cognitive functions Impairment in social
More informationUpdate on functional brain imaging in Movement Disorders
Update on functional brain imaging in Movement Disorders Mario Masellis, MSc, MD, FRCPC, PhD Assistant Professor & Clinician-Scientist Sunnybrook Health Sciences Centre University of Toronto 53 rd CNSF
More information212 Index C-SB-13,
Index A Acetylcholinesterase inhibitor, treatment, 15 Age-associated memory impairment (AAMI), 5 Alzheimer s disease (AD), 40, 95 96 apolipoprotein E genotype and risk for, 58 cellular neurodegeneration
More informationDementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
Dementia Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine What is Dementia? Dementia is a general term referring to a decline in cognitive/mental functioning; this decline
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationADNI and DIAN Neuropathology Core
NI and DIAN Neuropathology Core Update October 14, 2016 Nigel Cairns, PhD, FRCPath Knight RC Neuropathology Core Leader NI Participants Autopsied per Funding Period Autopsy rates for NI1, NI GO, and NI2
More information2/14/2013. The Pathogenesis of Parkinson s Disease. February, inherited forms of PD. Autosomal Recessive Parkinson s Disease
inherited forms of PD The Pathogenesis of Parkinson s Disease February, 2013 PARK1 dominant α-synuclein presynaptic protein PARK2 recessive parkin E3 ubiquitin ligase PARK3 dominant 2p13? PARK4 dominant
More informationDistinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation Article Published Version Creative Commons: Attribution 4.0 (CC BY) Open Access
More informationOverview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits
Overview Overview Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits The differential diagnosis of Parkinson s disease Primary vs. Secondary Parkinsonism Proteinopathies:
More informationCommon Versus Uncommon Causes of Dementia
Edith Cowan University Research Online ECU Publications Pre. 2011 2005 Common Versus Uncommon Causes of Dementia Nicola Lautenschlager University of Western Australia Ralph Martins Edith Cowan University
More informationDementia syndrome. Manifestation DISORDERS & DEMENTIA. Reasons of demencia
Manifestation DEGENERATIVE DISORDERS & DEMENTIA Roman Beňačka, MD,PhD Department of Pathophysiology Medical Faculty, Šafarik University Košice Increase in time required to retrieve information Less able
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationNIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2013 April 03.
NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2012 October ; 69(10): 1326 1331. doi:10.1001/archneurol.2012.1608. Pathologic Accumulation of α-synuclein and Aβ in
More informationC linicians have noted a close association between. Lewy body cortical involvement may not always predict dementia in Parkinson s disease PAPER
852 PAPER Lewy body cortical involvement may not always predict dementia in Parkinson s disease C Colosimo, A J Hughes, L Kilford, A J Lees... See end of article for authors affiliations... Correspondence
More informationKurt A. Jellinger. 2 nd Int. Conference BrainNet Europe, Munich, Dec , 2008 NAC A30P A53T ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH
2 nd Int. Conference BrainNet Europe, Munich, Dec. 10-12, 2008 NH 3 1 NAC 125 133 136 A30P A53T 125 140 ALPHA HELICAL HYDROPHOBIC ACID (GLU-PRO) COOH 29 71 82 125 129 (Src) (GRK5, CK-1 & CK-2) Kurt A.
More informationCASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?
CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.
More informationNeuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies
Article Neuropathological Substrates of Psychiatric Symptoms in Prospectively Studied Patients With Autopsy- Confirmed Dementia With Lewy Bodies Clive G. Ballard, M.R.C.Psych., M.D. Robin Jacoby, F.R.C.Psych.,
More informationOriginal Article Perivascular Neuritic Dystrophy Associated with Cerebral Amyloid Angiopathy in Alzheimer s Disease
www.ijcep.com/ijcep711002 Original Article Perivascular Neuritic Dystrophy Associated with Cerebral Amyloid Angiopathy in Alzheimer s Disease Kenichi Oshima, Hirotake Uchikado and Dennis W. Dickson Department
More informationTreatment of Neurological Disorders. David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018
Treatment of Neurological Disorders David Stamler, MD Chief Medical Officer and SVP, Clinical Development January, 2018 1 Corporate Overview Developing first-in-class therapies to treat orphan and non-orphan
More informationPerspectives on Frontotemporal Dementia and Primary Progressive Aphasia
Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Bradley F. Boeve, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Alzheimer s Disease
More informationJohnson, V. E., and Stewart, W. (2015) Traumatic brain injury: Age at injury influences dementia risk after TBI. Nature Reviews Neurology, 11(3), pp. 128-130. (doi:10.1038/nrneurol.2014.241) There may
More informationAtypical Progressive Supranuclear Palsy With Corticospinal Tract Degeneration
J Neuropathol Exp Neurol Copyright Ó 2006 by the American Association of Neuropathologists, Inc. Vol. 65, No. 4 April 2006 pp. 396Y405 ORIGINAL ARTICLE Atypical Progressive Supranuclear Palsy With Corticospinal
More informationLewy body pathology is a frequent co-pathology in familial Alzheimer s disease
Acta Neuropathol (2003) 105 : 484 488 DOI 10.1007/s00401-003-0670-9 REGULAR PAPER Yuri Trembath Carolyn Rosenberg John F. Ervin Donald E. Schmechel Perry Gaskell Margaret Pericak-Vance Jeffery Vance Christine
More informationCheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy
Cheyenne 11/28 Neurological Disorders II Transmissible Spongiform Encephalopathy -E.g Bovine4 Spongiform Encephalopathy (BSE= mad cow disease), Creutzfeldt-Jakob disease, scrapie (animal only) -Sporadic:
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationA Reassessment of the Lewy Body
Review Articles 40 A Reassessment of the Lewy Body Wing Lok Au 1,2 and Donald B. Calne 1 Abstract- Lewy body has been linked to Parkinson s disease for almost a century, but its significance in neurodegenerative
More informationIII./3.1. Movement disorders with akinetic rigid symptoms
III./3.1. Movement disorders with akinetic rigid symptoms III./3.1.1. Parkinson s disease Parkinson s disease (PD) is the second most common neurodegenerative disorder worldwide after Alzheimer s disease.
More informationDifferential Diagnosis
Differential Diagnosis 2 2.1 Introduction AD accounts for up to 75 % of all dementia cases. The differential diagnosis with other conditions is sometimes challenging since several disorders may produce
More informationLa neurosonologia. Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative. Nelle patologie degenerative e vascolari cerebrali
La neurosonologia Nelle patologie degenerative e vascolari cerebrali Andrea Pilotto Ecografia cerebrale e nuove applicazioni nelle malattie neurodegenerative Prof. Daniela Berg Department of Neurodegeneration
More informationAlzheimer Disease & Associated Disorders - An International Journal Spongiform Change in Dementia with Lewy Bodies and Alzheimer's Disease
Alzheimer Disease & Associated Disorders - An International Journal Spongiform Change in Dementia with Lewy Bodies and Alzheimer's Disease --Manuscript Draft-- Manuscript Number: Full Title: Article Type:
More informationThis is an author-deposited version published in: Eprints ID: 17837
Open Archive Toulouse Archive Ouverte (OATAO) OATAO is an open access repository that collects the work of Toulouse researchers and makes it freely available over the web where possible. This is an author-deposited
More informationAtypical Parkinsonian Disorders
APDs: Neuropathology and Nosology 111 Atypical Parkinsonian Disorders Neuropathology and Nosology 8 Charles Duyckaerts INTRODUCTION In many neurological diseases the topography of the lesion, whatever
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More informationWhat if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia
What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:
More informationDiagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16
The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationNovel Targets of disease modifying therapy for Parkinson disease. David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology
Novel Targets of disease modifying therapy for Parkinson disease David G. Standaert, MD, PhD John N. Whitaker Professor and Chair of Neurology Disclosures Dr. Standaert has served as a paid consultant
More information9.01 Introduction to Neuroscience Fall 2007
MIT OpenCourseWare http://ocw.mit.edu 9.01 Introduction to Neuroscience Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms. 9.01 Recitation (R02)
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationCaspase-Cleaved TAR DNA-Binding Protein-43 in Parkinson s Disease and Dementia with Lewy Bodies
Boise State University ScholarWorks Biology Faculty Publications and Presentations Department of Biological Sciences 6-1-2010 Caspase-Cleaved TAR DNA-Binding Protein-43 in Parkinson s Disease and Dementia
More informationVIII. 3. In vivo Visualization of α-synuclein Deposition by [ 11 C]BF-227 PET in Multiple System Atrophy
CYRIC Annual Report 2009 VIII. 3. In vivo Visualization of α-synuclein Deposition by [ 11 C]BF-227 PET in Multiple System Atrophy Kikuchi A. 1, Takeda A. 1, Okamura N. 2, Tashiro M. 3, Hasegawa T. 1, Furumoto
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationORIGINAL CONTRIBUTION. Diagnostic Accuracy of Dementia With Lewy Bodies. to be the second
ORIGINAL CONTRIBUTION Diagnostic Accuracy of Dementia With Lewy Bodies Ursula Hohl, MD; Pietro Tiraboschi, MD; Lawrence A. Hansen, MD; Leon J. Thal, MD; Jody Corey-Bloom, MD, PhD Background: Diagnostic
More informationOriginal Article Diversity of pathological features other than Lewy bodies in familial Parkinson s disease due to SNCA mutations
Am J Neurodegener Dis 2013;2(4):266-275 www.ajnd.us /ISSN:2165-591X/AJND1310002 Original Article Diversity of pathological features other than Lewy bodies in familial Parkinson s disease due to SNCA mutations
More informationVisual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe A. J. Harding, 1 G. A. Broe 1 and G. M. Halliday 1 Brain (2002), 125, 391±403 1 Prince of Wales Medical Research Institute
More informationOverview of neurological changes in Alzheimer s disease. Eric Karran
Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,
More informationORIGINAL CONTRIBUTION. Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia
ORIGINAL CONTRIBUTION Distinct Antemortem Profiles in Patients With Pathologically Defined Frontotemporal Dementia Murray Grossman, MD; David J. Libon, PhD; Mark S. Forman, MD, PhD; Lauren Massimo, LPN;
More informationAlzheimer's Disease A mind in darkness awaiting the drink of a gentle color.
Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer
More informationLewy Body Pathology Involves Cutaneous Nerves
J Neuropathol Exp Neurol Copyright Ó 2008 by the American Association of Neuropathologists, Inc. Vol. 67, No. 10 October 2008 pp. 945Y953 ORIGINAL ARTICLE Lewy Body Pathology Involves Cutaneous Nerves
More informationLANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION
LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION Murray Grossman University of Pennsylvania Support from NIH (AG17586, AG15116, NS44266, NS35867, AG32953, AG38490), IARPA, ALS Association, and the
More informationParkinson disease (PD) and dementia with Lewy bodies. Involvement of the Cerebellum in Parkinson Disease and Dementia with Lewy Bodies
BRIEF COMMUNICATION Involvement of the Cerebellum in Parkinson Disease and Dementia with Lewy Bodies Kay Seidel, PhD, 1 Mohamed Bouzrou, 1 Nina Heidemann, 1 Rejko Kr uger, MD, 2 Ludger Sch ols, MD, 3 Wilfred
More informationA Critical Review of Chronic Traumatic Encephalopathy
A Critical Review of Chronic Traumatic Encephalopathy Grant L. Iverson, Ph.D. Professor, Department of Physical Medicine and Rehabilitation, Harvard Medical School; Director, MassGeneral Hospital for Children
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationTHE RELATIONSHIP OF PLAQUES, TANGLES, AND LEWY TYPE ALPHA SYNUCLEINOPATHY TO VISUAL HALLUCINATIONS IN PARKINSON S DISEASE AND ALZHEIMER S DISEASE
THE RELATIONSHIP OF PLAQUES, TANGLES, AND LEWY TYPE ALPHA SYNUCLEINOPATHY TO VISUAL HALLUCINATIONS IN PARKINSON S DISEASE AND ALZHEIMER S DISEASE A Thesis submitted to the University of Arizona College
More informationProgressive Supranuclear Palsy: A Review of Co-existing Neurodegeneration
ORIGINAL ARTICLE Progressive Supranuclear Palsy: A Review of Co-existing Neurodegeneration J Keith-Rokosh, LC Ang ABSTRACT: Objectives: The neuropathological findings of 32 progressive supranuclear palsy
More informationALZHEIMER S DISEASE FACTOIDS & STATISTICS
ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10
More informationImaging biomarkers for Parkinson s disease
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 6 MDS-ES/EAN: Neuroimaging in movement disorders - Level 2 Imaging biomarkers for Parkinson
More informationCaring Sheet #11: Alzheimer s Disease:
CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses
More informationMultiple system atrophy (MSA) is a sporadic adult-onset
ORIGINAL RESEARCH E. Matsusue S. Fujii Y. Kanasaki T. Kaminou E. Ohama T. Ogawa Cerebellar Lesions in Multiple System Atrophy: Postmortem MR Imaging Pathologic Correlations BACKGROUND AND PURPOSE: Cerebellar
More informationORIGINAL CONTRIBUTION
ORIGINAL CONTRIBUTION Frontotemporal Lobar Degeneration Without Lobar Atrophy Keith A. Josephs, MST, MD; Jennifer L. Whitwell, PhD; Clifford R. Jack, MD; Joseph E. Parisi, MD; Dennis W. Dickson, MD Background:
More informationAlzheimer s Disease Neuroimaging Initiative
Alzheimer s Disease Neuroimaging Initiative Steering Committee Meeting April 18, 2016 Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Table 1. Participants Autopsied
More information